ASH 2021 Conference Coverage on VuMedi
ASH 2021 Long Term Follow-Up and Combined Phase 2 Results of Eprenetapopt & Azacitidine in Patients With TP53 Mutant MDS and Oligoblastic AML
By
ASH 2021 Conference Coverage on VuMedi
FEATURING
David Sallman
By
ASH 2021 Conference Coverage on VuMedi
FEATURING
David Sallman
Comments 0
Login to view comments.
Click here to Login
